Advancing the Clinical Understanding of MS: Emerging Concepts Presented at ACTRIMS 2024
March 1st 2024The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.
Read More
Children With SCD Exhibit Distinctive Palatal Rugae Patterns
February 29th 2024A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.
Read More
ACTRIMS 2024 Seeks to Explore and Break Barriers in MS
February 26th 2024The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).
Read More
The Promise of Frexalimab in MS Treatment: Part 1
February 26th 2024Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.
Read More
Hearing Impairment Disproportionately Affects Patients With SCD, Further Studies Required
February 9th 2024A cross-sectional comparative study demonstrated the increased prevalence of hearing impairment in children and adults with sickle cell disease (SCD) or sickle cell traits compared with healthy individuals.
Read More
Choroid Plexus Indicated in MS Pathology
February 9th 2024A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
Read More
COVID-19 Vaccination Rates Far Lower in Patients With SCD Compared With General Population
February 4th 2024A state-wide analysis draws attention to the fact individuals with sickle cell disease (SCD) completed a vaccination against COVID-19 at nearly half the rate of individuals without SCD.
Read More
Hospitalization, ER, and Medication Discontinuation Rates Still High in PNH
February 2nd 2024A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use despite the availability of multiple treatment options.
Read More
Evidence Linking Sleep to Improved Lower Back Pain Outcomes Is Weak, More Studies Needed
February 2nd 2024A systematic review of randomized controlled trials and prospective cohort studies concludes that sleep could be a prognostic component of lower back pain, but better evidence is needed.
Read More
Further Studies Required as MS DMT Exposure During Pregnancy Increases
February 1st 2024A large-scale, population-based study examined patterns of disease-modifying therapy (DMT) exposure in pregnant patients with MS since 2010, revealing increased occurrences and the need for future studies to examine the impact of newer-developed DMTs.
Read More
40-GEP Test Utilization Can Mitigate Financial Burden of Cutaneous Squamous Cell Carcinoma
February 1st 2024Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC) could save on health care costs by utilizing the 40-gene expression profile (40-GEP) to guide treatment decisions.
Read More
Health Discrepancies in Criminal Justice System Intrinsically Tied to Public Health
January 31st 2024Research on the state of health care, health outcomes, and health inequities in the criminal justice system continually advocates for structural-level reform and the recognition that carceral health issues are in fact public health issues.
Read More
Meta-Analysis Investigates Individual Components of CBT for Insomnia
January 29th 2024A meta-analysis explored the individual components of cognitive behavioral therapy for insomnia (CBT-I) and suggested that cognitive restructuring, stimulus control and sleep restrictions provide the more benefits to patients.
Read More
Myeloid Panel Analysis Imperative for Risk Assessment in Patients With CCUS
January 29th 2024A myeloid panel mutation analysis should be prioritized for patients with clonal cytopenia of undetermined significance (CCUS) as it can better assess patient risks for progression to a myeloid malignancy, a recent study argues.
Read More